Enovis Co. (NYSE:ENOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Enovis Co. (NYSE:ENOV) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $72.63.

A number of analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $82.00 price objective on shares of Enovis in a research note on Friday, May 3rd. JPMorgan Chase & Co. initiated coverage on shares of Enovis in a research note on Thursday, June 13th. They issued a “neutral” rating and a $53.00 price objective for the company.

Enovis Stock Performance

Shares of ENOV opened at $45.09 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.10 and a quick ratio of 1.03. The firm’s 50 day moving average is $50.70 and its 200-day moving average is $55.90. Enovis has a 12-month low of $43.04 and a 12-month high of $66.14. The stock has a market capitalization of $2.47 billion, a P/E ratio of -30.06 and a beta of 1.94.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.50 earnings per share for the quarter, hitting the consensus estimate of $0.50. The business had revenue of $516.00 million during the quarter, compared to analyst estimates of $505.62 million. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. The company’s revenue was up 27.0% compared to the same quarter last year. During the same period last year, the company posted $0.44 EPS. Equities research analysts anticipate that Enovis will post 2.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Enovis

Several institutional investors and hedge funds have recently modified their holdings of ENOV. Fidelis Capital Partners LLC acquired a new stake in Enovis during the first quarter valued at $34,000. Principal Securities Inc. bought a new stake in shares of Enovis in the 4th quarter valued at approximately $41,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of Enovis by 97.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 846 shares of the company’s stock valued at $47,000 after buying an additional 417 shares in the last quarter. GAMMA Investing LLC acquired a new position in Enovis in the fourth quarter worth approximately $53,000. Finally, DekaBank Deutsche Girozentrale bought a new position in Enovis during the first quarter valued at approximately $122,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.